House Committee Wants Answers On Foreign Inspections And Valsartan Crisis
Executive Summary
A bipartisan group of lawmakers is concerned about the growing number of recalls of blood pressure medicines from foreign manufacturing sites in China and India and wants answers from GAO and FDA.
You may also be interested in...
US FDA Warning Letter Draws Indian Solvent Recycler Into Valsartan Crisis
Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.
Novartis’ “Living Drugs”: Kymriah, Zolgensma – And Diovan?
Novartis is pioneering the new “living drugs” model. But its present financial performance benefits from regulatory problems that have beset generic competitors to a franchise written off for dead: the antihypertensive brand Diovan (valsartan).
Mutual Recognition's Next Evolution May Be Sharing Info On India And China Inspections
Now that US FDA has approved the final EU authority, mutual recognition efforts could expand and deepen. Former FDA chief counsel Rebecca Wood discusses the future of approval standards harmonization in Pink Sheet interview.